stockrow
Saturday 7 November 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
- Revenue
- +4,895.9%
- EPS
- +426.5%
- Free cash flow
- +25.7%
- Total debt
- +3.27%
Quarter to September 2026, against a year earlier
2.30
0.21
+10.05%
Follow ALEC
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
5.29 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.20 | 16.13 | 12.91 | 7.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.61) | (6.53) | (4.77) | (3.85) | |
P/B ratio |
1.79 | 0.00 | 22.90 | 5.24 | |
Price to Tangible BV |
1.79 | 0.00 | 22.90 | 5.24 | |
EV/Sales |
0.50 | 4.97 | 2.23 | (4.07) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.56 | |
EV/Operating CF |
(0.58) | (0.44) | (0.24) | 0.47 | |
EV/FCF |
(0.58) | (0.43) | (0.24) | 0.47 | |
Quick Ratio |
3.92 | 5.05 | 5.04 | 3.68 | |
Current Ratio |
4.10 | 5.26 | 5.25 | 3.83 | |
Net Debt/EBITDA |
0.00 | 7.16 | 8.40 | 6.40 | |
Debt/Assets |
0.00% | 4.85% | 4.07% | 3.30% | |
Debt/Equity |
0.00 | (0.99) | 0.94 | 0.32 | |
Asset Turnover |
0.69 | 0.05 | 0.06 | 0.06 | |
Operating CF/Net income |
(0.19) | 1.49 | 2.17 | 1.12 | |
Capex/Depreciation |
— | (0.02) | (0.08) | 0.00 | |
Research and Development Expense of Revenue |
18.44% | 586.14% | 1,707.17% | 520.49% | |
Selling, General and Administrative Expense of Revenue |
5.52% | 248.58% | 775.14% | 213.88% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.23% | 78.61% | 278.01% | 77.65% | |
Graham Net Nets |
0.46 | (0.15) | (0.06) | 0.02 | |
Graham Number |
2.86 | 1.49 | 0.00 | 0.00 | |
Earnings Yield |
18.92% | (54.73%) | (55.35%) | (89.10%) | |
Free Cash Flow Yield |
(72.10%) | (70.85%) | (72.84%) | (114.56%) | |
Revenue per Share |
1.45 | 0.03 | 0.01 | 0.06 | |
Operating CF per Share |
(0.21) | (0.31) | (0.45) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.31) | (0.45) | (0.40) | |
Cash per Share |
1.23 | 1.55 | 1.87 | 2.49 | |
Shareholders Equity per Share |
1.04 | (0.09) | 0.09 | 0.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | (0.09) | 0.09 | 0.30 | |
Free Cash Flow |
(24.15) | (34.25) | (49.93) | (41.69) | |
Working Capital |
109.93 | 145.85 | 174.12 | 196.95 | |
Capital Expenditures |
— | (0.03) | (0.12) | 0.00 | |
Net Current Asset Value |
96.14 | (32.74) | (14.45) | 3.86 | |
EV/EBIT |
2.50 | 0.00 | 0.00 | 0.55 | |
Capex to Sales |
0.00 | 0.01 | 0.11 | 0.00 | |
Price to Operating Income |
5.95 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.95 | 2.25 | 1.87 | 1.95 | |
Average Assets |
250.53 | 279.64 | 324.11 | 380.77 | |
Average Common Equity |
87.14 | 30.60 | 52.50 | 78.72 |
Columns are period end dates · fundamentals updated 5 Nov 2026